Tevogen (TVGN) Accounts Payables (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Accounts Payables came in at $3.8 million in Q1 2026, down 18.57% YoY from $4.7 million in Q1 2025, and up 13.73% on a QoQ basis from $3.3 million in Q4 2025.
Tevogen (TVGN) Accounts Payables (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Accounts Payables data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Accounts Payables fell 18.57% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 18.57% YoY) and the FY2025 annual result came in at $3.3 million, down 35.77% from the prior year.
- Accounts Payables rose to $3.8 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.7 million in Q2 2024 to a low of $128999.0 in Q1 2022.
- A 5-year average of $2.9 million and a median of $3.3 million in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 1524.29% — and 2025, when it tumbled 43.27%.
- Tracing TVGN's Accounts Payables over 5 years: stood at $210454.0 in 2022, then jumped by 1524.29% to $3.4 million in 2023, then jumped by 52.13% to $5.2 million in 2024, then plunged by 35.77% to $3.3 million in 2025, then grew by 13.73% to $3.8 million in 2026.
- The last three Accounts Payables figures came in at $3.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.80 Mn |
| Dec 31, 2025 | 3.34 Mn |
| Sep 30, 2025 | 3.31 Mn |
| Jun 30, 2025 | 4.24 Mn |
| Mar 31, 2025 | 4.66 Mn |
| Dec 31, 2024 | 5.20 Mn |
| Sep 30, 2024 | 5.84 Mn |
| Jun 30, 2024 | 6.67 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 694,918.00 |
| Mar 31, 2023 | 485,074.00 |
| Dec 31, 2022 | 210,454.00 |
| Sep 30, 2022 | 171,783.00 |
| Jun 30, 2022 | 179,234.00 |
| Mar 31, 2022 | 128,999.00 |
| Dec 31, 2021 | 39,375.00 |